[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336654-105":59,"doc-detail-336654-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","nab-paclitaxel-plus-capecitabine-for-advanced-biliary-tract-cancers-phase-ii-open-label-non-randomized-trial","Nab-paclitaxel plus capecitabine for advanced biliary tract cancers - Phase II open-label non-randomized trial","","BACKGROUND: Biliary tract cancers are heterogeneous, highly malignant tumors with poor prognosis and limited treatment options. AIM: To evaluate efficacy and safety of nab-paclitaxel plus capecitabine as first-line therapy for advanced and metastatic biliary tract cancers. METHODS: This open-label, non-randomized, double-center phase II trial enrolled systemic therapy-naive patients with unresectable or metastatic disease between April 2019 and June 2022. Nab-paclitaxel (150 mg/m2 day 1) and capecitabine (2000 mg/m2 twice daily, days 1-7) were given in 14-day cycles until progression or intolerable toxicity. RESULTS: 44 patients completed treatment; ORR was 23.26% and DCR 69.77%. Median OS was 14.1 months and median PFS 4.4 months. Adverse events occurred in 93.18%, with grade ≥3 AEs in 22.73%, and no treatment-related deaths. CONCLUSION: The regimen may be an effective and safe first-line strategy for this population.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nab-paclitaxel-plus-capecitabine-for-advanced-biliary-tract-cancers-phase-ii-open-label-non-randomized-trial/336654/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nab-paclitaxel-plus-capecitabine-for-advanced-biliary-tract-cancers-phase-ii-open-label-non-randomized-trial/336654.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of this phase II trial?","Question",{"text":112,"@type":113},"The study aimed to assess the efficacy and safety of nab-paclitaxel plus capecitabine as first-line treatment for advanced and metastatic biliary tract cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who were the eligible participants and how was treatment administered?",{"text":117,"@type":113},"Systemic therapy-naive patients with unresectable or metastatic biliary tract cancers were enrolled. They received nab-paclitaxel and capecitabine in 14-day cycles until progression or intolerable toxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key efficacy outcomes?",{"text":121,"@type":113},"Among patients with imaging assessment, the objective response rate was 23.26% and disease control rate was 69.77%. Median overall survival was 14.1 months and median progression-free survival was 4.4 months.",{"name":123,"@type":110,"acceptedAnswer":124},"How did safety results compare across participants?",{"text":125,"@type":113},"Adverse events occurred in 93.18% of patients, and 22.73% experienced grade ≥3 adverse events. Common events included alopecia, leukopenia, neutropenia, and liver dysfunction, with no treatment-related deaths reported.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},336654,1790189348,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","| W | J | G | World Journal of\u003Cbr>Gastroenterology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastroenterol 2024 August 14; 30(30): 3564-3573  \nDOI: 10.3748/wjg.v30.i30.3564 ISSN 1007-9327 (print) ISSN 2219-2840 (online)  \nORIGINAL ARTICLE  \nClinical Trials Study  \nNab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial  \nLing-Xiao Xu, Jia-Jia Yuan, Ran Xue, Jun Zhou  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nUnsolicited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade B, Grade C  \nNovelty: Grade B, Grade B  \nCreativity or Innovation: Grade B, Grade B  \nScientific Significance: Grade B, Grade B  \nP-Reviewer: Rodrigues-Pinto E; Tzang BS  \nReceived: June 5, 2024  \nRevised: July 8, 2024  \nAccepted: July 16, 2024  \nPublished online: August 14, 2024  \nProcessing time: 65 Days and 1.9 Hours  \nLing-Xiao Xu, Jia-Jia Yuan, Ran Xue, Jun Zhou, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China  \nCorresponding author: Jun Zhou, MD, Chief Doctor, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, [China.](China. joelbmu@126.com)[ joelbmu@126.com](China. joelbmu@126.com)  \nAbstract  \nBACKGROUND  \nBiliary tract cancers (BTCs) are a heterogeneous group of tumors with high malignancy, poor prognosis, and limited treatment options.  \nAIM  \nTo explore the efficacy and safety of nab-paclitaxel plus capecitabine as first-line treatment for advanced and metastatic BTCs.  \nMETHODS  \nThis open-label, non-randomized, double-center, phase II clinical trial recruited systemic therapy-naive patients with unresectable or metastatic BTCs between April 2019 and June 2022 at Beijing Cancer Hospital and the First Hospital of China Medical University. Eligible patients were administered nab-paclitaxel (150 mg/m2, day 1) and capecitabine (2000 mg/m2, twice daily, days 1-7) in 14-day cycles until experiencing intolerable toxicity or disease progression. The primary outcome was the objective response rate (ORR) . The secondary outcomes included the disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and safety.  \nRESULTS  \nA total of 44 patients successfully completed the trial, with a median age of 64.00 years (interquartile range, 35.00-76.00), and 26 (59.09%) were females. Tumor response assessment was impeded for one patient due to premature demise from tumor hemorrhage. Among the remaining 43 patients undergoing at least one imaging assessment, the ORR was 23.26%[95% confidence interval (CI): 11.80% - 38.60%], and the DCR was 69.77%(95%CI: 53.90%-82.80%) . The median OS was  \n WJG  [https://www.wjgnet.com](https://www.wjgnet.com) 3564 August 14, 2024  Volume 30  Issue 30   \nXu LX et al. Nab-paclitaxel + capecitabine for BTCs  \n14.1 months (95%CI: 8.3-19.9), and the median PFS was 4.4 months (95%CI: 2.5-6.3). A total of 41 patients (93.18%) experienced at least one adverse event (AE), with 10 patients (22.73%) encountering grade ≥ 3 AEs, and the most frequent AEs of any grade were alopecia (79.50%), leukopenia (54.55%), neutropenia (52.27%), and liver dysfunction (40.91%), and no treatment-related deaths were documented.  \nCONCLUSION  \nNab-paclitaxel plus capecitabine may be an effective and safe first-line treatment strategy for patients with advanced or metastatic BTCs.  \nKey Words: Nab-paclitaxel; Capecitabine; Biliary tract cancer; Objective response rate; Phase II clinical trial  \n©The Author(s) 2024. P","cbCaimOCSEHsrhqc","https://ap.wps.com/l/cbCaimOCSEHsrhqc","pdf",696770,11,"English","# Abstract\n## Background and Aim\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the purpose of this phase II trial?\",\"answer\":\"The study aimed to assess the efficacy and safety of nab-paclitaxel plus capecitabine as first-line treatment for advanced and metastatic biliary tract cancers.\"},{\"question\":\"Who were the eligible participants and how was treatment administered?\",\"answer\":\"Systemic therapy-naive patients with unresectable or metastatic biliary tract cancers were enrolled. They received nab-paclitaxel and capecitabine in 14-day cycles until progression or intolerable toxicity.\"},{\"question\":\"What were the key efficacy outcomes?\",\"answer\":\"Among patients with imaging assessment, the objective response rate was 23.26% and disease control rate was 69.77%. Median overall survival was 14.1 months and median progression-free survival was 4.4 months.\"},{\"question\":\"How did safety results compare across participants?\",\"answer\":\"Adverse events occurred in 93.18% of patients, and 22.73% experienced grade ≥3 adverse events. Common events included alopecia, leukopenia, neutropenia, and liver dysfunction, with no treatment-related deaths reported.\"}]","Nab-paclitaxel plus capecitabine for advanced biliary tract cancers - Phase II open-label non-randomized trial | PDF",1790016054,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b743090c4f570ec8b5a3d13e22e4ce02.webp",983,1390,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7c829e010007f76eebda2a2ed278ca8.webp",982,1389,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b88b2a1dc1017a55d09cf50774e75846.webp",981,1387,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a505af697b9266aa92bce383ce3ce886.webp",980,1386]